EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Temozolomide and ruxolitinib combination modulates miRNA-associated regulatory networks in glioblastoma stem cells

Neslihan Pinar Ozates, Aycan Asik, Bakiye Goker Bagca, Cigir Biray Avci

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05506-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Neslihan Pinar Ozates und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Faculty of Medicine, Harran University, Sanliurfa, Turkey. neslihan.ozates@harran.edu.tr. Hauptthemen laut MEDLINE: MicroRNAs, Glioblastoma, Temozolomide, Pyrazoles. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Harran University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma is an aggressive primary brain tumor characterized by high recurrence rates and resistance to standard therapies, including temozolomide (TMZ). Emerging evidence suggests that microRNAs (miRNAs) play a critical role in regulating treatment response and tumor progression. In this study, we investigated the effects of TMZ and the JAK inhibitor ruxolitinib, alone and in combination, on miRNA expression profiles in glioblastoma cancer stem cells. miRNA expression levels were analyzed using quantitative real-time PCR, and differential expression was evaluated using the 2 −ΔΔCt method. TMZ treatment increased the expression of oncogenic miRNAs, including hsa-miR-19a-3p, hsa-miR-221-3p, and hsa-miR-10a-5p, whereas ruxolitinib treatment reduced their expression levels. Combination treatment attenuated the TMZ-induced upregulation of these miRNAs. Bioinformatics analyses were performed to identify target genes and associated signaling pathways. Predicted targets were obtained using TargetScan and further supported by experimentally validated interactions from miRTarBase. KEGG pathway enrichment analysis revealed significant associations with cancer-related pathways, including PI3K-Akt, MAPK, Wnt, and Hippo signaling pathways. Network analysis highlighted key genes such as BCL2L11, PTEN, and SOCS family members. Overall, our findings suggest that TMZ may induce oncogenic miRNA expression as part of an adaptive response, while ruxolitinib may counteract this effect. Targeting miRNA-mediated regulatory networks in combination with pathway inhibition may represent a promising strategy to overcome therapeutic resistance in glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsGlioblastomaTemozolomidePyrazolesBrain NeoplasmsNeoplastic Stem CellsAntineoplastic Combined Chemotherapy ProtocolsHumansNitrilesPyrimidinesCell Line, TumorGene Expression Regulation, NeoplasticGene Regulatory NetworksSignal Transduction

Stichwörter der Autor:innen

CombinationMiRNARuxolitinibTemozolomide

Substanzen

MicroRNAsruxolitinibTemozolomideNitrilesPyrimidinesPyrazoles

Autor:innen und Institutionen

  • Department of Medical Biology, Faculty of Medicine, Harran University, Sanliurfa, Turkey. neslihan.ozates@harran.edu.tr.
  • Department of Medical Biology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey.
  • Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey.

Förderung

  • Harran University

Zitieren

APA

Ozates, N. P., Asik, A., Bagca, B. G., & Avci, C. B. (2026). Temozolomide and ruxolitinib combination modulates miRNA-associated regulatory networks in glioblastoma stem cells. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05506-3

Vancouver

Ozates NP, Asik A, Bagca BG, Avci CB. Temozolomide and ruxolitinib combination modulates miRNA-associated regulatory networks in glioblastoma stem cells. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05506-3

BibTeX
@article{Ozates2026,
  author = {Ozates, Neslihan Pinar and Asik, Aycan and Bagca, Bakiye Goker and Avci, Cigir Biray},
  title = {Temozolomide and ruxolitinib combination modulates miRNA-associated regulatory networks in glioblastoma stem cells},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05506-3}
}
Kostenlos starten →